Key Takeaways
- All-time high U.S. revenue, margin at upper end: North America hit a quarterly record of $230 mn (+18% YoY), while EBITDA margin expanded to 26.3%, tracking at the higher end of the 23–24% guided range.
- India chronic portfolio leads, trade generics and consumer health add legs: One-India grew 12%, with the chronic portfolio outpacing the market at 13% growth, supported by deepening trade generics distribution and a recovering Cipla Health business.
- Regulatory overhang persists but a path is visible: An Indore warning letter requires remediation, while the Goa facility, key to the Abraxane launch, is due for reinspection starting Q1 next fiscal. Both timelines are now management’s central unlock for the U.S. pipeline.
- Peptide pipeline is the next growth vector, but specifics are thin: Four launches are planned for FY25, with one asset awaiting approval for a Q1 launch; management declined to size the market or fully break down IP versus approval risk.
- What to watch next quarter: Whether Goa gets an FDA reinspection date, the Q1 peptide launch materializes, and the full-year U.S. sales guidance management promised to deliver on the next call.
U.S. Business: Record Revenue, Regulatory Unlocks
- Quarterly revenue hit an all-time high of $230 mn, up 18% YoY, driven by positive volume traction from seasonality and base business demand.
- Leuprolide supply issues are resolved, with higher offtake this quarter and a scale-up expected in the next quarter or the one after.
- Lanreotide market share is expected to rise incrementally, with marginal increases still on the cards.
- Albuterol data resubmitted to the FDA; management stated all parts of the product are safe and efficacious and the team is guided to improve share without rushing.
- Advair pricing pressure is manageable because the innovator’s list price cut matters less than the net price, which is already around $30 per inhaler after rebating and discounts.
- Management declined to say whether U.S. sales can exceed $1 bn in the next few quarters, deferring any view on the U.S. market to the end-of-quarter guidance call.
Umang Vohra: "We can safely say that all parts of the product are safe and efficacious and that we believe that there is a natural phenomenon of these products."
Regulatory Pathway: Indore Warning Letter, Goa Reinspection Clock
- Indore facility received a warning letter following the February 2023 audit; the company has responded to all queries and is now focused on remediation.
- Goa facility has submitted all pending acquisitions and was last inspected in August 2022, putting it on a two-year clock for reinspection starting Q1 of the next fiscal.
- Generic Abraxane (nanopaclitaxel) launch timing hinges entirely on Goa: if the reinspection clears, the launch will be ahead of management’s estimate; if no inspection occurs or it does not clear, the product is further delayed. A third-party site transfer is also underway but will take longer.
- Symbicort is a single-site filing from Indore currently; a second site transfer has been completed and will be added to the file once queries are received, so by the time of approval (2+ years), two sites will be in the file.
Umang Vohra: "If Goa -- our thinking is that Goa should be due any time for inspection from starting with quarter 1 of the year because it was inspected in August of 2022. So, on a 2-year clock -- sorry, it should be ready for reinspection starting from a quarter 1 of fiscal year -- of the next fiscal. So therefore, actually, that is -- if that inspection clears, then actually nanopaclitaxel will be ahead of market -- ahead of our estimate if that inspection clears."
India & Branded Markets: Chronic Strength, Distribution Depth
- One-India revenue grew 12% backed by branded prescription, trade generics and consumer health; the chronic portfolio outpaced the market with 13% growth, led by respiratory, cardiac and urology.
- Trade generics performance was supported by order book execution, new introductions, deepening distribution and technology to improve reach.
- Consumer health returned to growth YoY, supported by leading brands and stronger reported brand equity, albeit in a slower market; operating profitability remains sustainable. Cipla Health is now back on a growth trajectory after a slow start from a beverages market slowdown and inventory rebalancing.
- South Africa prescription grew 7% in the secondary market versus a 2% market, inching closer to the market leader; tender and OTC businesses also saw positive traction.
- Cipla Global Access tender business for the rest of Africa posted YoY growth supported by order book execution.
- India domestic business will target higher-than-market growth next year by expanding into Tier 2 through Tier 6 for volume growth.
Pipeline & Portfolio: Peptides Arrive, Respiratory Stays Core
- One peptide asset is ready and awaiting approval, with a launch definitely planned for Q1 FY25; it would be the first generic if approved, and the market size is fairly significant. Management declined to disclose the market size or number of existing players.
- Four peptide launches are planned in FY25, with additional 505(b)(2) opportunities and complex products in the works; management later clarified it is five launches next year.
- IP versus approval risk split on the peptide assets is close to 50-50, per management, though they initially declined to quantify it. Most IP issues for selected assets will resolve in the FY24–FY25 timeframe.
- Respiratory will remain the largest category; peptides will be meaningful but smaller.
- Advair filing is expected mid-FY25, with data submitted from a new site versus the old site; FDA review should take 6–9 months, likely closer to 6, putting potential approval toward the end of next fiscal.
- Pulmazole was fully impaired this quarter; the company may continue developing and launching the asset in India and other markets.
Margins & Capital Allocation: Mix-Led Expansion, Cash Deployment Ahead
- EBITDA margin reached 26.3%, expanding on a favourable mix, calibrated price action across branded and generic portfolios, and easing cost inflation.
- Gross margin improved 90 bps YoY to 66% driven by pricing, a better Chronic mix in Q2 and Q3, and lower procurement costs for key APIs; this level is likely sustainable, but no meaningful expansion is expected next year because the WPI pricing advantage will not repeat.
- Other expenses (ex-R&D) delivered 50 bps of savings as a percentage of revenue over the first nine months, driven by cost control and lower clinical studies costs; this is a sustainable level.
- R&D spend was INR 400 crores (6.1% of revenue), up 10% YoY, and the ~6% trend is expected to continue for the next couple of years.
- The balance sheet is net cash positive; all long-term loans including ZAR 72 crore of term debt in South Africa have been repaid. The board will take a call on cash distribution by year-end, factoring in India growth aspirations, U.S. inorganic launches, international opportunities and CapEx.
- Inorganic approach will not compromise on IRRs; bolt-on acquisitions in markets with limited capital allocation are preferred, while India can see more aggressive sizing. Cipla Health continuously looks at brands to acquire, but not large platforms.
Strategy & Positioning: Specialty Ambition, Pricing Cycle Realism
- U.S. specialty strategy is a FY27–FY28 story: if 1–2 assets get to market by then, that would validate in-house capability and could trigger acquisition of in-market assets. Management is currently shy of investing in anything with development risk, citing limited therapy-area diligence strength.
- The U.S. pricing cycle is in year 1+ or year 2 of a down cycle, per management; the general trend is a full up or down cycle every 3–4 years, and within a year things will be very different. Pricing will not constantly stay in the 4–6% deflation range.
- Samina Vohra stepped down from the executive vice-chair role but continues as a non-executive director; the move was driven by a promoter family plan to create an institution that survives various promoter transitions. Management stated there is no promoter stake sale and no discussion or dialogue on one over the last 2–3 months.
Umang Vohra: "Maybe our understanding of this therapy is not -- of therapies is not strong enough to do diligence on these assets."
Umang Vohra: "There is no sale. There is no -- as of this moment, there is no sale, and there hasn't been any discussion or any information or any dialogue over the last at least 2 to 3 months that we are aware of."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Peptide asset launch | First peptide asset definitely launched; first generic if approved | Q1 FY25 |
| Peptide launches | 4 launches planned in FY25 (later clarified as 5) | FY25 |
| Advair filing | Submit data from new site to FDA | Mid-FY25 |
| Advair approval | FDA review of 6–9 months, likely closer to 6 months | End of next fiscal (FY25) |
| Goa reinspection eligibility | Facility due for reinspection on 2-year clock from Aug 2022 inspection | Starting Q1 next fiscal |
| Abraxane launch | Launch ahead of estimate if Goa inspection clears; delayed if no inspection or it fails | Conditional on Goa clearance |
| U.S. market guidance | Management will provide a view on the U.S. market | End of this quarter (next call) |
| R&D spend | Trend of ~6% of revenue continuing | Next couple of years |
| EBITDA margin | Full year trending at higher end of guided range | FY24 (23–24% range) |
| India domestic growth | Target higher than market growth, expanding into Tier 2–6 | Next year |
Key Metrics
| Metric | Q3 FY24 |
|---|---|
| Revenue | ₹6,544 cr, +14% YoY |
| EBITDA margin | 26.3%, does not include other income |
| Gross margin after material cost | 66.3%, +90 bps YoY |
| Profit after tax | ₹1,049 cr, 16% of sales |
| Effective tax rate | 27.5%, constant |
| R&D investment | ₹400 cr, 6.1% of revenue, +10% YoY |
| Total expenses (employee + other) | ₹2,621 cr, flat sequentially |
| Cash and equivalents | ₹7,591 cr |
| Gross debt | ₹449 cr, lease liabilities and working capital facilities only; all long-term loans repaid including ZAR 72 cr term debt in South Africa |
| Return on invested capital | ~29%, trailing 12 months |
| One-India business growth | +12% YoY |
| Chronic portfolio growth | +13% vs IPM growth of 11% (IQVIA MAT December '23) |
| Chronic therapy share | 60.3%, +115 bps YoY |
| North America quarterly revenue | $230 million, all-time high, +18% YoY, 15th consecutive quarter of YoY growth |
| Lanreotide market share | 20% |
| SAGA growth ex-QCIL | +35% YoY in USD terms |
| South Africa prescription secondary growth | +7% vs market growth of 2% (IQVIA MAT November '23) |
| Branded prescription brands >₹100 cr | 20 brands (IQVIA MAT December '23) |
| Trade generics brands >₹50 cr | 8 brands |
| Cipla Health anchor brands >₹100 cr | 5 brands, trailing 12 months |
| Full-year EBITDA margin guidance | Trending at higher end of 23% to 24% guided range |
| U.S. generic price compression band | Currently in the 4% to 6% range |
| CapEx typical annual range | ₹1,000 to ₹1,500 cr |
| Loss on sale of QCIL | ~₹18 cr, booked in other income |
| Advair estimated net price | ~$30 per inhaler |